An observational study in Acute Hypoxemic Respiratory Failure, sponsored by Hospital del Mar Research Institute (IMIM). Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Hospital del Mar Research Institute (IMIM) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Respiratory Insufficiency with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Respiratory Insufficiency · Spain.
Among the 69 studies in Respiratory Insufficiency with a site in Spain, this one is the 14th largest by planned enrollment of the 31 observational ones that give a count, is one of 5 that started in 2026, is one of 31 observational ones, reaches primary completion later than 14 of the 14 other live ones, and was the 65th registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.
Browse Respiratory Insufficiency studies →11 of the 69 studies in Respiratory Insufficiency with a site in Spain are open now. Recruiting first, the newest first:
Medipol University · Sites in Spain, Chile, Egypt and 3 more countries
Ages 18–89
Centro de Emergencias Sanitarias 061 Andalucía · Sites in Spain
BioAegis Therapeutics Inc. · Sites in Spain, United States, Belgium and 10 more countries
Ages 18+
University Health Network, Toronto · Sites in Spain, United States, Australia and 7 more countries
Ages 18+
Parc Taulí Hospital Universitari · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 100 across 456 observational studies indexed under Respiratory Insufficiency.
Median enrollment 116 across the 38 interventional studies, 298 across the 31 observational. Of the 42 that completed or were terminated, 6 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 69 have an industry lead sponsor. The 10 most frequent:
Hospital del Mar Research Institute (IMIM) is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Hospital del Mar Research Institute (IMIM) has 3 studies filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
7 of the studies in Respiratory Insufficiency with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07679646Air Liquide Healthcare SpainEffectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO) | 2026-12 |
| NCT07098611Medipol UniversityA New Tool for Extubation Readiness in Mechanically Ventilated Patients: Readiness for EXtubation Score | 2026-12-30 |
| NCT07178483Hospital Universitari de BellvitgeEvaluation of Physical Capacity and Energy Requirements in Patients With Hypoxemic Acute Respiratory Failure | 2027-03-01 |
| NCT05440851University Health Network, TorontoPlatform of Randomized Adaptive Clinical Trials in Critical Illness | 2027-03-31 |
| NCT07708506Jesus VillarIs Hypoxemia Driving Outcome in Acute Hypoxemic Respiratory Failure? (HOMELAND Study) | 2027-07-29 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Respiratory Insufficiency with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to determine whether metabolomic profiles combined with clinical data can predict high-flow nasal cannula (HFNC) failure and help optimize respiratory support in adult patients with acute hypoxemic respiratory failure (AHRF). The main questions it aims to answer are:
Can metabolomic biomarkers identify patients at higher risk of HFNC failure? Does combining metabolomic and clinical data improve the prediction of respiratory support escalation and clinical outcomes?
Participants will:
Receive standard HFNC treatment according to clinical practice. Undergo collection of clinical, physiological, and laboratory data. Provide blood samples for metabolomic analysis during respiratory support.
This observational study aims to evaluate whether metabolomic signatures combined with routinely collected clinical and physiological data can improve the prediction of high-flow nasal cannula (HFNC) failure in patients with acute hypoxemic respiratory failure (AHRF). HFNC is widely used as first-line non-invasive respiratory support in AHRF; however, delayed recognition of treatment failure may lead to worse clinical outcomes, including delayed intubation and increased morbidity and mortality.
The study will prospectively enroll adult patients with AHRF treated with HFNC. Clinical variables, respiratory parameters, laboratory results, and patient outcomes will be collected during routine clinical care. Blood samples will also be obtained for metabolomic analysis to identify molecular profiles associated with HFNC success or failure.
The primary objective is to identify metabolomic and clinical predictors associated with HFNC failure and escalation of respiratory support. Secondary objectives include evaluating the association between metabolomic patterns and relevant clinical outcomes such as endotracheal intubation, duration of respiratory support, intensive care unit (ICU) length of stay, and mortality. The study also aims to develop predictive models integrating biological and clinical data to support personalized respiratory management strategies in AHRF.
Adult patients admitted to intensive care units (ICUs) with acute hypoxemic respiratory failure (AHRF) requiring treatment with high-flow nasal cannula (HFNC) as part of routine clinical care. Participants will be prospectively recruited from tertiary-care hospitals in Catalonia, Spain, including: Hospital del Mar, Hospital de Bellvitge, Hospital Parc Taulí, Hospital Joan XXIII
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with acute hypoxemic respiratory failure receiving high-flow nasal cannula (HFNC) as part of routine clinical care. Clinical, physiological, and metabolomic data will be collected to evaluate predictors of HFNC failure and respiratory support escalation.
HFNC Failure
Failure of high-flow nasal cannula (HFNC), defined as the need for invasive mechanical ventilation in patients with acute hypoxemic respiratory failure (AHRF).
Time frame: Within the first 28 days after HFNC initiation.
Predictive Performance of the Metabolomic-Clinical Model
Comparison of the predictive accuracy of the metabolomic-clinical model versus the ROX index for predicting HFNC failure.
Time frame: Baseline and within the first 24 hours after HFNC initiation.
ICU Mortality
All-cause mortality during ICU admission.
Time frame: Up to ICU discharge or 28 days.
Duration of Respiratory Support
Duration of HFNC therapy and invasive mechanical ventilation among patients requiring intubation.
Time frame: Up to 28 days.
Association Between Metabolomic Profiles and Clinical Phenotypes
Association between metabolomic biomarkers and clinical phenotypes according to sex, age, and etiology of acute hypoxemic respiratory failure.
Time frame: Baseline, day 3, and day 5.
Plan to share: Undecided — Both male and female participants will be included. Sex-specific metabolomic analyses will be explored as part of the study objectives.
Started Jun 2026 (actual). Primary completion is estimated for May 2029, 35 months after the start.
Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 35 months is above that.
Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital del Mar Research Institute (IMIM)